Kerber R, Reindl S, Romanowski V, Gómez R M, Ogbaini-Emovon E, Günther S, ter Meulen J
Department of Virology, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, Germany.
Instituto de Biotecnología y Biología Molecular, CCT-La Plata, CONICET-UNLP, La Plata, Argentina.
J Clin Virol. 2015 Mar;64:120-7. doi: 10.1016/j.jcv.2014.12.004. Epub 2014 Dec 18.
Significant progress has been made in the past 10 years in unraveling the molecular biology of highly pathogenic arenaviruses that are endemic in several West African countries (Lassa fever virus) and in some regions of South America (Argentine and Bolivian hemorrhagic fever viruses). While this has resulted in proof-of-concept studies of novel vaccine candidates in non-human primates and in the discovery of several novel antiviral small molecule drug candidates, none of them has been tested in the clinic to date. The recent Ebola outbreak in West Africa has demonstrated very clearly that there is an urgent need to develop the prophylactic and therapeutic armamentarium against viral hemorrhagic fever viruses as part of a global preparedness for future epidemics. As it pertains to this goal, the present article summarizes the current knowledge of highly pathogenic arenaviruses and identifies opportunities for translational research.
在过去十年中,在揭示高致病性沙粒病毒的分子生物学方面取得了重大进展,这些病毒在几个西非国家(拉沙热病毒)以及南美洲的一些地区(阿根廷出血热病毒和玻利维亚出血热病毒)流行。虽然这已在非人类灵长类动物中进行了新型候选疫苗的概念验证研究,并发现了几种新型抗病毒小分子候选药物,但迄今为止,它们都尚未在临床上进行测试。最近在西非爆发的埃博拉疫情非常清楚地表明,迫切需要开发针对病毒性出血热病毒的预防和治疗手段,作为全球应对未来疫情准备工作的一部分。关于这一目标,本文总结了高致病性沙粒病毒的现有知识,并确定了转化研究的机会。